The overarching goal of Dr. Mulsant’s research work over more than two decades has been to improve the treatment of persons with severe mental disorders. He has authored and co-authored more than 320 journal articles and book chapters. He has been funded by NIMH and CIHR since 1992. His long-term scientific focus has been on designing and conducting clinical trials for “hard–to-treat” older patients with severe mental disorders: geriatric depression, psychotic depression, late–life bipolar disorder, schizophrenia, and dementia. Over the past decade, his collaborators and he have been involved in efforts to identify biomarkers associated with late-life mental disorders based on new advances in pharmacogenetics and neuroimaging. In April 2014, he received a $10M grant from Brain Canada to study the efficacy of a combination of transcranial Direct Current Stimulation (tDCS) and cognitive remediation in the prevention of Alzheimer’s disease in high-risk patients. He is also leading a new study of telephone-based integrated collaborative care to improve the outcomes of depression, anxiety, and problem drinking in primary care patients.
Dr. Mulsant is a Professor and the Labatt Family Chair of the Department of Psychiatry at the University of Toronto, and a clinician scientist at the Centre for Addiction and Mental Health in Toronto (CAMH).
He has authored and co-authored more than 490 peer-reviewed articles and 63 book chapters and invited publications. Over the past 25 years, he has been an investigator on grants with funding totaling more than $170M in direct costs (including more than $72M as principal investigator or team leader) funded, among others, by Brain Canada, the Canada Institutes for Health Research, the US Patient-Centered Outcomes Research Institute, and the US National Institute of Health. The over-arching goal of his work is to improve the treatment of older persons with severe mental disorders. His small clinical practice focuses on older patients with mood disorders and cognitive disorders (dementia). He has been listed in Best Doctors in America and Best Doctors in Canada.
Dr. Mulsant earned his MD from the Laval University, Quebec; he completed his internship in internal medicine and neurology at the Royal Victoria Hospital and the Montreal Neurological Institute, McGill University; and his residency in psychiatry at Western Psychiatric Institute and Clinic, University of Pittsburgh. He is a Fellow of the Royal College of Physicians and Surgeons of Canada; a Diplomate in Psychiatry, American Board of Psychiatry and Neurology; and a Distinguished Fellow of the American Psychiatric Association.
Dr. Mulsant est professeur et directeur du département de psychiatrie à l’université de Toronto, et un responsable scientifique au centre de toxicomanie et de santé mentale à Toronto (CAMH).
Il est l’auteur de plus de 490 publications scientifiques et 63 chapitres et éditoriaux. Durant les 25 dernières années, il a été chercheur d’études cliniques qui ont reçu plus de 170 millions de dollar de subvention (dont plus de 72 millions en tant que chercheur principal) de la Fondation Neuro Canada, du Patient-Centered Outcomes Research Institute des États-Unis (PCORI), des Instituts de recherche en santé du Canada, du National Institute of Health des États-Unis, et par plusieurs fondations. L'objectif principal de son travail de recherche est d'améliorer le traitement des personnes âgées atteintes de troubles mentaux graves. Sa pratique clinique est axée sur les patients âgés atteints de troubles de l'humeur et de troubles cognitifs (démence). Il a été sur les listes des Meilleurs médecins au Canada et Best Doctors in America.
Dr. Mulsant a obtenu son doctorat en médecine à l’université Laval et il a complété son internat en médecine interne à l’hôpital Royal Victoria à Montréal et sa résidence en psychiatrie à l’université de Pittsburgh. Il est un associé (Fellow) du Collège royal des médecins et chirurgiens du Canada; un diplomate en psychiatrie, American Board of Psychiatry and Neurology; et Distinguished Fellow of the American Psychiatric Association.